Abstract:Metabolic syndrome is a disorder based on insulin resistance. Metabolic syndrome is diagnosed by a co-occurrence of three out of five of the following medical conditions: abdominal obesity, elevated blood pressures, elevated glucose, high triglycerides, and low high-density lipoprotein-cholesterol (HDL-C) levels. Clinical implication of metabolic syndrome is that it increases the risk of developing type 2 diabetes and cardiovascular diseases. Prevalence of the metabolic syndrome has increased globally, particularly in the last decade, to the point of being regarded as an epidemic. The prevalence of metabolic syndrome in the USA is estimated to be 34% of adult population. Moreover, increasing rate of metabolic syndrome in developing countries is dramatic. One can speculate that metabolic syndrome is going to induce huge impact on our lives. The metabolic syndrome cannot be treated with a single agent, since it is a multifaceted health problem. A healthy lifestyle including weight reduction is likely most effective in controlling metabolic syndrome. However, it is difficult to initiate and maintain healthy lifestyles, and in particular, with the recidivism of obesity in most patients who lose weight. Next, pharmacological agents that deal with obesity, diabetes, hypertension, and dyslipidemia can be used singly or in combination: anti-obesity drugs, thiazolidinediones, metformin, statins, fibrates, renin-angiotensin system blockers, glucagon like peptide-1 agonists, sodium glucose transporter-2 inhibitors, and some antiplatelet agents such as cilostazol. These drugs have not only their own pharmacologic targets on individual components of metabolic syndrome but some other properties may prove beneficial, i.e. anti-inflammatory and anti-oxidative. This review will describe pathophysiologic features of metabolic syndrome and pharmacologic agents for the treatment of metabolic syndrome, which are currently available.

Drug Delivery Strategies for the Treatment of Metabolic Diseases

Drug Delivery System in the Treatment of Diabetes Mellitus

Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap.

Advances in metformin-delivery systems for diabetes and obesity management

New Therapeutic Approaches in the Management of Cardiometabolic Diseases: Bringing the Concepts Together.

Nanomedicine-based potential phyto-drug delivery systems for diabetes

Therapeutics in Metabolic Diseases

An apprise on novel drug delivery systems for management of diabetes mellitus

Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease

Exploring Innovative Approaches in Type-2 Diabetes Management: A Comprehensive Review on Nano-carriers and Transdermal Drug Delivery

Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development

Cardiovascular Drug Delivery

Unveiling the potential of prodrug and drug-conjugate strategies in treatment of diabetes mellitus and its complications

Recent Advances in the Drugs and Glucose-Responsive Drug Delivery Systems for the Treatment of Diabetes: A Systematic Review

Nanotechnology‐Mediated Drug Delivery for the Treatment of Obesity and Its Related Comorbidities

Intelligent Drug Delivery: Pioneering Stimuli-Responsive Systems to Revolutionize Disease Management - An In-depth Exploration

Carrier Systems for Advanced Drug Delivery: Improving Drug Solubility/Bioavailability and Administration Routes

Leveraging Physiology for Precision Drug Delivery

A New Strategy for Obesity Treatment: Revealing the Frontiers of Anti-obesity Medications

Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities

Pharmacological treatment and therapeutic perspectives of metabolic syndrome